Your browser doesn't support javascript.
loading
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
Kristeleit, Rebecca; Shapiro, Geoffrey I; Burris, Howard A; Oza, Amit M; LoRusso, Patricia; Patel, Manish R; Domchek, Susan M; Balmaña, Judith; Drew, Yvette; Chen, Lee-May; Safra, Tamar; Montes, Ana; Giordano, Heidi; Maloney, Lara; Goble, Sandra; Isaacson, Jeff; Xiao, Jim; Borrow, Jen; Rolfe, Lindsey; Shapira-Frommer, Ronnie.
Affiliation
  • Kristeleit R; Research Department of Oncology, UCL Cancer Institute, London, United Kingdom. r.kristeleit@ucl.ac.uk.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Burris HA; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee.
  • Oza AM; Department of Obstetrics and Gynecology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • LoRusso P; Department of Medical Oncology, Yale University, New Haven, Connecticut.
  • Patel MR; Department of Medical Oncology, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
  • Domchek SM; Department of Medical Oncology, Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Balmaña J; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Drew Y; Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom.
  • Chen LM; Department of Obstetrics, Gynecology, and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Safra T; Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Montes A; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Giordano H; Department of Medical Oncology, Guy's Hospital, London, United Kingdom.
  • Maloney L; Clinical Science, Clovis Oncology, Inc., Boulder, Colorado.
  • Goble S; Clinical Science, Clovis Oncology, Inc., Boulder, Colorado.
  • Isaacson J; Biostatistics, Clovis Oncology, Inc., Boulder, Colorado.
  • Xiao J; Statistics and Data Management, Clovis Oncology, Inc., Boulder, Colorado.
  • Borrow J; Clinical Pharmacology and Nonclinical DMPK, Clovis Oncology, Inc., Boulder, Colorado.
  • Rolfe L; Clinical Development, Clovis Oncology, Inc., Boulder, Colorado.
  • Shapira-Frommer R; Clinical and Preclinical Development, Clovis Oncology, Inc., Boulder, Colorado.
Clin Cancer Res ; 23(15): 4095-4106, 2017 Aug 01.
Article in En | MEDLINE | ID: mdl-28264872
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma / BRCA1 Protein / BRCA2 Protein / Indoles Type of study: Guideline / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Carcinoma / BRCA1 Protein / BRCA2 Protein / Indoles Type of study: Guideline / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Year: 2017 Type: Article